Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Canopy Growth Corp — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.49, while Canopy Growth Corp trades at $1 (market cap $399.40M). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| BIL | CGC | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $1.92 |
52-Week Low | $91.27 | $0.86 |
Market Cap | — | $399.40M |
Enterprise Value | — | $356.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.
As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.
CGC trades at $0.9701, up 4.07% in 24 hours, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year but continues to post net losses, with a negative net income margin of -92.38% in 2026. Cash flow trends show improving operational efficiency, though negative operating cash flow persists. Recent news highlights progress on profitability measures and anticipation of U.S. cannabis rescheduling decisions.
The outlook remains cautious due to persistent unprofitability and regulatory uncertainties, but cost-cutting and revenue growth offer potential upside. Key risks include high debt, competitive pressures, and delayed federal cannabis reforms. Analysts are divided, reflecting the stock's high-risk, high-reward profile amid ongoing turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
